|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
For more information on The Center for Cancer Prevention and Treatment, please call
(714) 734-6200.
|
|
Trial Name:
IRB #09-029: SWOG 0702 - A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment |
Protocol Number:
IRB #09-029 |
Stage:
Stage IV |
Trial Type:
Osteonecrosis of the Jaw |
Description:
This is an observational research study designedto learn how often osteonecrosis of the jaw (ONJ) occurs in patients withcancer in their bones who are being treated with zoledronic acid (Zometa)during a 3 year time period after starting Zometa. This study will also identify risk factorsassociated with ONJ. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #09-030: NSABP B-46-I - A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer |
Protocol Number:
IRB #09-30 |
Stage:
Stage I-IIIB |
Trial Type:
|
Description:
The mainpurpose of this study is to learn if adding a drug called bevacizumab totreatment with two chemotherapy drugs for early stage HER2-negative breastcancer will prevent breast cancer from returning. A secondpurpose of this study is to learn if adding bevacizumab to treatment with docetaxeland cyclophosphamide will help women with HER2-negative breast cancer livelonger. The researchers also want to learn about the sideeffects of the combination of drugs used in this study. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #09-027: NSABP B-43 - A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy |
Protocol Number:
IRB #09-027 |
Stage:
DCIS |
Trial Type:
|
Description:
This study isbeing done to compare the effects, good and/or bad, of adding the drugtrastuzumab (also called Herceptin®) to breast radiationtherapy. Radiation therapy is thestandard treatment after surgery for patients with ductal carcinoma in situ (DCIS). DCIS is a very early stage of breastcancer. Participants in this study must be HER2 positive, havehad a lumpectomy to remove the DCIS and plan to have breast radiation therapyafter surgery. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #09-026: RTOG 0614 - A Randomized, Phase III, Double-blind, Placebo-controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-brain Radiotherapy |
Protocol Number:
IRB #09-026 |
Stage:
Stage IV |
Trial Type:
|
Description:
The purpose of this research study is to comparethe effects, good and/or bad, of memantine (a medication approved by the Foodand Drug Administration (FDA) for the treatment of Alzheimer’s dementia) with aplacebo (a pill with no active ingredients) on memory and thinking inparticipants receiving whole brain radiotherapy. Memantine is a medication that helps protectcertain areas of the brain from too much stimulations by chemical substances inthe brain, called neurotransmittors. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #08-025: NSABP B-41 - A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response |
Protocol Number:
IRB #08-025 |
Stage:
Neo-Adjuvant |
Trial Type:
|
Description:
The overproduction of the protein HER2 can causenormal cells to pick up too many growth signals which can turn a normal cellinto a cancer cell and can change the way a cancer cell responds to treatment. This study is for patients with invasiveHER2-positive breast cancer and have not yet had surgery to remove the tumor will be given lapatinib with standard breast cancertreatments. Lapatinib is a new therapyfor HER2-positive breast cancer. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #09-009: Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study |
Protocol Number:
IRB #09-009 |
Stage:
Stage I/II |
Trial Type:
|
Description:
The purpose of this research study is to monitor the feasibility and outcome of the Active Surveillance Program for men with low risk prostate cancer. Active Surveillance has emerged as a viable option enabling many patients to avoid for years or possibly altogether the significant costs and potential long-term side effects of prostate cancer treatments, such as urinary control issues, bowel dysfunction and impotence (an inability to have or maintain an erection). |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #09-008: MedWaves: Microwave Ablation of Resectable Liver Tumors |
Protocol Number:
IRB #09-008 |
Stage:
Any Stage |
Trial Type:
|
Description:
The purpose of this research study is to evaluate the effect of microwave ablation on liver cancers. Microwave ablation is a procedure that uses heat from microwave energy to destroy cancer cells. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #09-015: Nutritional Screening in Head & Neck Cancer Patients |
Protocol Number:
IRB #09-015 |
Stage:
Any stage |
Trial Type:
Data collection study |
Description:
The purpose of this research study is to determine what tests can best show us potential problems with nutrition in persons with head and neck cancer (HNC). |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #09-010: University of Pittsburgh: Phase II Randomized Trial of Radiation, Cetuximab and Pemetrexed with or without Bevacizumab in Locally Advanced Head and Neck Cancer |
Protocol Number:
IRB #09-010 |
Stage:
III/IV |
Trial Type:
Head and Neck |
Description:
The purpose of this research study is to compare the effects (good and bad) of chemoradiotherapy with or without Bevacizumab (Avastin) for previously untreated locally advanced head and neck cancer. Chemoradiotherapy is the combination of chemotherapy (the drugs pemetrexed and cetuximab) and radiation. After completing the study, patients will be seen every 3 months for 2 years and then every 6 months for 3 years, and subsequently annually for a total of 10 years from study initiation. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #08-029: TheraSphere: A Treatment of Unresectable Hepatocellular Carcinoma with TheraSphere |
Protocol Number:
IRB #08-029 |
Stage:
III-IV |
Trial Type:
Liver |
Description:
The purpose of this HDE treatment protocol is to provide access to TheraSphere treatment to patients with liver cancer who cannot be treated by surgical removal of the tumor. The objective of treatment with TheraSphere is to selectively administer a radioactive material to neoplastic tissue in the liver of patients with hepatocellular carcinoma. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #08-039: Margin Probe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery |
Protocol Number:
IRB #08-039 |
Stage:
N/A |
Trial Type:
Breast |
Description:
The purpose of this research study is to show whether the addition of a hand held device during a routine lumpectomy procedure is beneficial and assists the surgeon in correctly determining the extent of the lumpectomy procedure. The probe may identify small cancer cell clusters to be removed at the time of initial surgery and therefore void the need for repeat surgery. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #08-019: E2804: The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma |
Protocol Number:
IRB #08-019 |
Stage:
III-IV |
Trial Type:
Renal |
Description:
The purpose of this study is to compare the effects, good and/or bad of several different treatments for metastatic renal cell carcinoma. In this study you will get one regimen for as long as it prevents growth of your cancer.It is believed that combinations of two anti-cancer treatments may be superior to any one therapy alone. This study is designed to determine which of the four drug regimens should be tested in later clinical trials. You will be assigned to one of the following experimental arms: Arm A [bevacizumab (Avastin)]; Arm B [bevacizumab (Avastin) and temsirolimus (Torisel)]; Arm C [bevacizumab (Avastin) and sorafenib (Nexavar)]; or Arm D [temsirolimus (Torisel) and sorafenib (Nexavar)]. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #08-010: RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy |
Protocol Number:
IRB #08-010 |
Stage:
Stage 1 |
Trial Type:
Prostate |
Description:
The purpose of this research study is to compare the effects, good and/or bad of three treatment methods on patients and their cancer.There are 3 treatment groups in this study:(1) Patients who receive radiation therapy to the prostate bed only; (2) Patients who receive hormone therapy for 4 to 6 months plus radiation therapy to the prostate bed; (3) Patients who receive hormone therapy for 4 to 6 months plus radiation therapy to the prostate bed and to the pelvic lymph nodes. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #08-009: E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC) |
Protocol Number:
IRB #08-009 |
Stage:
IB-IIIA |
Trial Type:
Lung |
Description:
The purpose of this study is to determine if adding the new drug bevacizumab (Avastin) to chemotherapy improves the chance for cure for patients who have had surgery for the removal of their lung cancer. The effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on a patient’s lung cancer to see which is better at preventing the cancer from coming back. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #07-030: B-40: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect of Pathologic Complete Response (pCR) of adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC with or without bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with each of the Regimens |
Protocol Number:
IRB #07-030 |
Stage:
Neoadjuvant |
Trial Type:
Breast |
Description:
One of the main purposes of the study is to learn how breast cancer tumors respond to several different chemotherapy combinations. Three of the chemotherapy drugs used in this study are docetaxel followed by the combination of doxorubicin and cyclophosphamide, a standard treatment for breast cancer. This study will add the drug capecitabine and the drug gemcitabine to docetaxel to see if either drug improves the effectiveness of the standard drugs at killing all of the tumor cells in the breast and nearby lymph nodes.A second main purpose of the study is to learn how breast cancer tumors like respond when the drug bevacizumab is added to the combinations of chemotherapy in this study. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #07-049: B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer |
Protocol Number:
IRB #07-049 |
Stage:
I-IIIA |
Trial Type:
Breast |
Description:
The main purpose of the study is to learn whether or not continuing hormonal therapy with an AI called letrozole for 5 additional years after already taking 5 years of hormonal therapy (which included an AI) can further reduce the chance of breast cancer returning. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #08-011: Spectrum: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer |
Protocol Number:
IRB #08-011 |
Stage:
0 (Ta or G1/G2) |
Trial Type:
Treatment |
Description:
The purpose of this research study is to determine if treatment with EOquin, an investigational drug for bladder cancer will prevent or delay a return of low-grade bladder cancer following surgery. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #07-022: GlaxoSmithKline: A Double-blind, Randomized, Placebo-controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer |
Protocol Number:
IRB #07-022 |
Stage:
IB-IIIA |
Trial Type:
Lung |
Description:
The purpose of this study is to test a new kind of anti-cancer treatment that may prevent recurrence of non-small cell lung cancer after surgery and also after chemotherapy if you receive chemotherapy after surgery. This anti-cancer treatment is a vaccine. However, it cannot be applied to all types of lung cancers – the cancer must produce a protein called MAGE-A3. The study will help determine if the vaccine works, and if it does, to measure the cancer’s response to treatment. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #07-044: University of Nebraska: Microarray Analysis of Patients with Diffuse Large B-Cell Lymphoma Treated with CHOP/Rituximab |
Protocol Number:
IRB #07-044 |
Stage:
I-IV |
Trial Type:
Lymphoma |
Description:
There are two portions of this study: prospective and retrospective. The prospective study is for patients whose physicians plan using CHOP/Rituximab for treating their diffuse large b-cell non-Hodgkin’s lymphoma (DLBCL). The retrospective study is for patients who were treated initially with CHOP/Rituximab for DLBCL. The goal of both studies is to assess the prognosis for patients with this type of lymphoma by studying the activity of the genes in the lymph nodes along with other patient clinical information. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
Trial Name:
IRB #07-050: CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum |
Protocol Number:
IRB #07-050 |
Stage:
IV |
Trial Type:
Colorectal |
Description:
The purpose of this study is to determine if the addition of cetixumab to FOLFIRI or FOLFOX chemotherapy with and without bevacizumab prolongs survival compared to FOLFIRI or FOLFOX with bevacizumab in patients with untreated, advanced or metastatic colorectal cancer. |
Contact Information:
Cancer.ClinicalTrials@stjoe.org |
| Contact us for more informaon about this clinical trial. |
|
 |
|
|
|